Paula F. Ypma

St. Antonius Ziekenhuis
Nieuwegein, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Hemostatic and platelet proteins are associated with bleeding grade and time to major bleed in hemato-oncological patients.

Hemostatic and platelet proteins are associated with bleeding grade and time to major bleed in hemato-oncological patients.

Journal: Blood vessels, thrombosis & hemostasis

Published: October 07, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Journal: HemaSphere

Published: July 31, 2025

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.

Journal: Haematologica

Published: July 10, 2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Journal: Blood advances

Published: June 09, 2025

Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study.

Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 05, 2025

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

Journal: EClinicalMedicine

Published: April 20, 2025

Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato-oncological patients.

Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato-oncological patients.

Journal: Transfusion

Published: April 14, 2025

Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab.

Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab.

Journal: Bone marrow transplantation

Published: November 26, 2024

Sexuality and bleeding in von Willebrand disease.

Sexuality and bleeding in von Willebrand disease.

Journal: Research and practice in thrombosis and haemostasis

Published: November 18, 2024

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.

Journal: American journal of hematology

Published: October 29, 2024

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.

Journal: Blood

Published: June 25, 2024

Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

Journal: HemaSphere

Published: June 03, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026